AdvaMed Pushes Predictable Tariffs and Faster FDA Review Paths
Tariffs, FDA user-fee renewal, payment clarity and cybersecurity sit at the center of AdvaMed’s current policy agenda. Scott Whitaker, the organization’s president and CEO, laid out those priorities at the MedTech Conference in Boston, framing them as the conditions that shape whether medical technology companies can build, ship, clear and protect products at scale.
The list is short, but the business implications are broad. Each item affects a different layer of the device ecosystem: manufacturing costs, regulatory throughput, reimbursement access and the security of the increasingly connected devices that now move clinical data across hospitals, homes and remote monitoring platforms. For device makers, instability in any one of those domains can slow product adoption long before a clinician ever sees the technology at the bedside.
A predictable policy environment has become as important to medtech strategy as engineering or clinical validation.
Tariff Volatility Is a Direct Operating Problem
Whitaker’s first priority was tariffs, and his preference is a zero-tariff model. If that is not possible, he said, AdvaMed wants tariffs kept low and made more predictable. The reason is practical and immediate: medical technology companies operate global supply chains, and shifting tariff levels can disrupt sourcing, pricing and long-term planning.
His concern centered on volatility rather than any single duty rate. A company can model around a 5% or even a 10% tariff more easily than around abrupt swings from 5% to 25% and back again. That kind of uncertainty can ripple through procurement contracts, manufacturing budgets and downstream hospital pricing. In a sector where margins already absorb regulatory, quality and logistics costs, tariff instability becomes a structural drag on innovation.
FDA User Fees Remain a Core Regulatory Lever
The second priority is renewal of the FDA’s medical device user-fee program, known as MDUFA. Under the program, companies pay fees when they submit premarket applications or register facilities, and those fees support the agency’s review capacity and regulatory efficiency. The current proposal, MDUFA VI, covers fiscal years 2028 through 2032 and is waiting on congressional action.
Whitaker emphasized process quality as the key issue. The medtech industry depends on a review system that is consistent enough to support development timelines and capital allocation. When the review pathway works, it allows smaller firms and larger manufacturers alike to plan clinical studies, production schedules and market launches with some degree of confidence. When it slows or becomes less reliable, the entire product pipeline tightens.
Regulatory predictability is not an abstract policy goal in medtech; it is the difference between a product waiting in development and a product entering clinical use.
Payment and Coverage Rules Still Lag Behind FDA Certainty
The third priority is payment policy, and Whitaker’s comments drew a sharp contrast between the relative predictability of FDA review and the far less predictable payer environment. Clearance from the FDA does not guarantee that a product will be covered, nor does it ensure that federal payers will understand how the technology should be reimbursed in real-world care.
That gap matters because payment uncertainty can block adoption even after regulatory approval. Device makers may have a clinically sound product, yet still face a long and opaque path before hospitals, physicians and health systems can use it routinely. Whitaker said coverage and payment are both important, but he placed special weight on understanding what federal payers need in order to cover a product today.
For a medtech company, reimbursement ambiguity can be as consequential as a rejected submission. The FDA may determine whether a device can enter the market, but coverage decisions often determine whether it can reach patients at scale. Clearer rules would make it easier for innovators to forecast sales, for providers to plan implementation and for investors to support technologies that need time to gain traction.
Connected Care Raises the Stakes for Cybersecurity
Whitaker’s fourth priority moves beyond reimbursement and regulation into digital infrastructure. AdvaMed is placing greater emphasis on data access, cybersecurity and the systems that support connected care. As devices become more networked, they also become more exposed to operational and security threats that can affect both clinical workflow and patient trust.
The issue is especially relevant for technologies that rely on continuous data exchange, remote monitoring or software-linked functionality. In those settings, security is not just an IT concern. It is part of device performance and, in some cases, part of patient safety. A compromised connected device can interrupt care delivery, disrupt data flow or force health systems to delay deployment while they reassess risk.
Cybersecurity now sits beside reimbursement and regulation as a core medtech policy issue because modern devices are no longer isolated tools. They are part of an integrated care environment in which information must move reliably and securely.
What Medtech Needs from Washington Now
The four priorities Whitaker described point to a single theme: the industry wants a steadier operating environment. Tariff predictability would help companies manage global production. MDUFA renewal would preserve a functioning review structure. Better payment and coverage transparency would reduce uncertainty after FDA clearance. Stronger cybersecurity expectations would protect the digital backbone of connected care.
Each of those areas affects a different stage of the product lifecycle, but they converge on the same outcome. Medtech innovation advances faster when the rules are clear enough for companies to plan around and durable enough for clinicians and health systems to trust. The remaining challenge is not identifying the pressure points; it is turning them into policy that can survive shifting political and budget priorities.